דוסיטקסל טבע ® 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון

Land: Israel

Sprog: hebraisk

Kilde: Ministry of Health

Aktiv bestanddel:

DOCETAXEL 27.73 MG / 1 ML

Tilgængelig fra:

ABIC MARKETING LTD

ATC-kode:

L01CD02

Lægemiddelform:

CONCENTRATE AND SOLVENT FOR SOLUTION FOR INFUSION

Indgivelsesvej:

I.V

Fremstillet af:

PHARMACHEMIE B.V., THE NETHERLANDS

Terapeutisk gruppe:

DOCETAXEL

Terapeutiske indikationer:

Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have inclu

Autorisation dato:

2011-06-01